M.M. Dillon & Co acted as a financial advisor to Cardax Inc (OTC CDXI ) in its registered public exchange offer for 27.5 million warrants into newly issued warrants and…
M.M. Dillon acted as an advisor to Windstream Communications (NYSE WIN) in the contested spin off and related debt exchange for $542 million working with company counsel Kirkland & Ellis.…
MM Dillon acted as an advisor to CareDx, Inc. (Nasdaq:CDNA) the completion of its previously announced acquisition of publically traded Allenex AB. The acquisition included a successful tender of 98.37%…
MM Dillon was retained by Boies, Schiller & Flexner LLP as a financial consultant for the benefit of their clients, Douglas A. Kelley, Trustee et al (the “Trustees”) of the…
MM Dillon acted as a financial advisor to ContraFect Corporation (CFRX), in its underwritten public offering of 32,000,000 shares of its common stock and related warrants to purchase 16,000,000 shares…
M.M. Dillon & Company (“Dillon”) acted as sole financial advisor to QuantaSol Ltd. In its sale to JDSU (NASDAQ: JDSU). JDSU is now Viavi Solutions. Terms of the transaction were…
MM Dillon advised Inovio in the spin-off of GENEOS Therapeutics, Inc., to develop and commercialize neo-antigen based personalized cancer therapies. While Inovio pursues the unique potential of its SynCon® immunotherapy…
CRT Investment Banking LLC n/k/a M.M. Dillon & Co. served as financial advisor and expert witness to Molecular Insight Pharmaceuticals, Inc. in connection with the Company’s chapter 11 bankruptcy in…
Cell Therapeutics, Inc. (“Cell Therapeutics” or the “Company”) engaged M.M. Dillon & Co. (“Dillon”) to privately place $82,000,000 of 5 year, 6.75% Convertible Senior Notes. The notes were issued under…
MM Dillon advised the minority shareholders of Texas Spine & Joint Hospital (TSJH) which has partnered with Baylor Scott & White Health (BSWH) and United Surgical Partners International (USPI). MM…